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Myelodysplastic syndromes (MDS) are an array of blood disorders that result in defective maturation 
of one or multiple blood cell lineages, including white blood cells, red blood cells, and platelets. 
About one-third of patients with MDS progress to acute myeloid leukemia (AML). MDS is a clonal 
disorder thought to arise by mutations in bone marrow stem cells, although the precise causes are 
largely unknown. Both mutations in MDS cells, and interactions with the bone marrow 
microenvironment contribute to the broad range of clinical manifestations of MDS. Many cytokines 
and signals are upregulated in the MDS bone marrow microenvironment that can induce apoptosis, 
including tumor necrosis factor α (TNFα). Clonal MDS cells are less responsive to these signals in 
early stage MDS and grow increasingly resistant to apoptosis in advanced stages of disease, 
outcompeting normal cells for space in the marrow. To uncover the mechanism of apoptosis 
resistance, researchers from Dr. Joachim Deeg’s lab in the Clinical Research Division, including lead 
author and postdoctoral fellow Dr. Xiang Li and Associate in Clinical Research Dr. Mario Marcondes, 
have elucidated how the interaction between the bone marrow microenvironment and precursor 
MDS cells modulates expression of the transcription factor TWIST-1 to regulate microRNA 
expression and apoptotic signaling. 
In a previous study (Li et al., 2010), Dr. Li had shown that expression of the transcription factor 
TWIST-1 is increased in MDS precursor cells. TWIST-1 negatively regulates apoptosis by binding to 
and inhibiting the pro-apoptotic protein p53. Primary MDS cells or myeloid cell lines with high levels 
of TWIST-1 expression were co-cultured with a stromal cell line and treated with TNFα to replicate 
the bone marrow microenvironment. Upon co-culture, TWIST-1 expression was decreased and p53 
expression increased in the MDS cells, which in turn increased TNFα-induced apoptosis of the co-
cultured MDS cells. Silencing of TWIST-1 expression by RNA interference further enhanced TNFα-
induced apoptosis in cells co-cultured with stroma. This effect was partially mediated through p53-
dependent expression of the pro-apoptotic protein BAX. 
In the current study, Li et al. examined MDS patient cells for changes in expression of microRNAs 
(miRs), small non-coding RNAs 19-25 nucleotides in length. MiRs regulate a variety of cell 
processes, including hematopoiesis and apoptosis, by fine-tuning protein expression through mRNA  
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degradation or inhibition of protein translation. Levels of miR-10a and miR-10b were significantly 
higher in 28 MDS patient samples compared to normal bone marrow cells sorted for the 
hematopoietic precursor cell surface marker CD34 (miR-10a p=0.05, and miR-10b p=0.012). 
TWIST-1 is a known transcriptional regulator of miR-10a/b expression, and the levels of miR-10a/b 
expression correlated with TWIST-1 protein levels in primary MDS cells (miR-10a, R=+0.69, 
p<0.0001; miR-10b, R=+0.56, p=0.0008) and in a subset of myeloid cell lines. Furthermore, silencing 
TWIST-1 expression by RNA interference in myeloid cell lines decreased miR-10a/b expression, 
confirming that miR-10a/10b expression is transcriptionally controlled by TWIST-1. 
To examine the role of miR-10a/b in apoptosis resistance, miR-10a and miR-10b were stably 
knocked down in the myeloid cell lines KG1a and PL-21 and the cells were co-cultured with stromal 
cells. Apoptosis was significantly enhanced in the knock-down cells after exposure to TNFα. 
Importantly, miR-10a/b silencing increased activity of the p53 promoter, as well as p53-dependent 
expression of the pro-apoptotic proteins BAX and BID. This result was similar to the previous study 
involving TWIST-1 knockdown. To address how miR-10a/b specifically controlled p53 and apoptosis, 
the authors examined the transcription factor NF-κB, which modulates the ability of p53 to induce 
gene expression. They showed miR-10a/b specifically targets and decreases expression of the 
protein TAK-1, which controls the nuclear translocation and activity of NF-κB by altering 
phosphorylation of the inhibitor of NF-κB (I-κB). By decreasing TAK-1 levels, miR-10a/b blocks the 
activity of NF-κB and thus p53 induced apoptotic proteins. Taken together, elevated TWIST-1 
expression increases miR-10a/b expression, which in turn inhibits p53 and NF-κB activity to mediate 
apoptosis resistance in MDS clonal cells. This regulatory network could be targeted therapeutically 
to treat advanced MDS. 
  
Li X, Xu F, Chang C, Byon J, Papayannopoulou T, Deeg HJ, Marcondes AM. 2012.Transcriptional 
regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes. Haematologica. Epub ahead of 
print. doi: 10.3324/haematol.2012.071753 
Also see: Li X, Marcondes AM, Gooley TA, Deeg HJ. 2010. The helix-loop-helix transcription factor 
TWIST is dysregulated in myelodysplastic syndromes. Blood. 116(13): 2304-14. 
November 19, 2012 SCIENCE SPOTLIGHT 
 
3 Volume 2, Issue 11 | Fred Hutchinson Cancer Research Center 
 
 
Image adapted from manuscript with authors’ permission 
Transcription factor TWIST-1 induces miR-10a/b 
expression in MDS clonal cells. A) RNA was harvested 
from CD34+ sorted precursor bone marrow cells from 
MDS (n=28) and healthy (n=13) patients. MiR-10a and 
miR-10b expression was significantly increased in MDS 
versus healthy cells as determined by Nanostring 
analysis. B) Schematic representation of the proposed 
regulatory network. TWIST-1 induces miR-10a/b 
expression, which in turn targets TAK-1 to block NF-ΚB 
and p53 activity to mediate apoptosis resistance in MDS 
cells. 
 
